ReviewOncotarget2016
Proteomics and peptidomics: moving toward precision medicine in urological malignancies.
Review in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Bioactive Peptides From theFood science & nutrition · 2026Review
- Mass Spectrometry Proteomics: A Key to Faster Drug Discovery.Journal of medicinal chemistry · 2026Review
- Revolutionizing renal biopsy: the emerging role of omics and artificial intelligence in nephrology.Frontiers in medicine · 2025Review
- Clinical Peptidomics in Acute Leukemias: Current Advances and Future Perspectives.Journal of proteome research · 2024Review
- Preliminary investigation on the impact of salty and sugary former foods on pig liver and plasma profiles using OMICS approaches.Scientific reports · 2024Article
- Peptidomics Strategies to Evaluate Cancer Diagnosis, Prognosis, and Treatment.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Deciphering Urogenital Cancers through Proteomic Biomarkers: A Systematic Review and Meta-Analysis.Cancers · 2023Review
- Neurobiochemical, Peptidomic, and Bioinformatic Approaches to Characterize Tauopathy Peptidome Biomarker Candidates in Experimental Mouse Model of Traumatic Brain Injury.Molecular neurobiology · 2023Article
- Circulating Peptidome Is Strongly Altered in COVID-19 Patients.International journal of environmental research and public health · 2023Article
- Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease.International journal of molecular sciences · 2022Article
- OMICS in Chronic Kidney Disease: Focus on Prognosis and Prediction.International journal of molecular sciences · 2021Review
- Urinary Protein and Peptide Markers in Chronic Kidney Disease.International journal of molecular sciences · 2021Review
- Review
- Mining the Biomarker Potential of the Urine Peptidome: From Amino Acids Properties to Proteases.International journal of molecular sciences · 2021Review
- Effects of Psychological Intervention on Perioperative Quality of Life and Serum PSA and FPSA Levels of Patients with Prostate Cancer Treated with Integrated Traditional Chinese and Western Medicine.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Peptidomics and Capillary Electrophoresis.Advances in experimental medicine and biology · 2021Article
- Bioinformatic Analysis of the Wound Peptidome Reveals Potential Biomarkers and Antimicrobial Peptides.Frontiers in immunology · 2020Article
- Urinary Peptidomic Biomarkers in Kidney Diseases.International journal of molecular sciences · 2019Review
- Review
- Peptidome profiling dataset of ovarian cancer and non-cancer proximal fluids: Ascites and blood sera.Data in brief · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urological malignancies are a major cause of morbidity and mortality worldwide. Advances in early detection, diagnosis, prognosis and prediction of treatment response can significantly improve patient care. Proteomic and peptidomic profiling studies are at the center of kidney, prostate and bladder cancer biomarker discovery and have shown great promise for improved clinical assessment. Mass spectrometry (MS) is the most widely employed method for proteomic and peptidomic analyses. A number of MS platforms have been developed to facilitate accurate identification of clinically relevant markers in various complex biological samples including tissue, urine and blood. Furthermore, protein profiling studies have been instrumental in the successful introduction of several diagnostic multimarker tests into the clinic. In this review, we will provide a brief overview of high-throughput technologies for protein and peptide based biomarker discovery. We will also examine the current state of kidney, prostate and bladder cancer biomarker research as well as review the journey toward successful clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.